As part of his work in high-energy particle physics, Prof. Yasar Onel and his team have invented a scintillator that would be used in an ultra-fast radiation treatment for cancer.

Inventions of two University of Iowa College of Engineering faculty members have been licensed for commercial use. They are the latest technology transfer examples in which research emerging from UI laboratories is spun-out to a private company for broader public benefit.

Perspective, Therapeutics, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents based in-part on IP licensed from UIRF, and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis.

Cardio Diagnostics Holdings, Inc., a pioneering precision cardiovascular medicine company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, today announced that China’s Patent Office has issued a Notice of Allowance to the University of Iowa Research Foundation (“UIRF”) for Chinese Patent Application No. 201780049286.4.

The University of Iowa Lichtenberger Engineering Library is now part of a select group of higher education institutions across the country—and only one in Iowa—to be designated a Patent and Trademark Resource Center (PTRC) by the U.S. Patent and Trademark Office (USPTO).

South Korean food giant CJ CheilJedang Corp. announced on Tuesday that it has signed a license contract with Emmyon, an University of Iowa biotechnology startup, to utilize Emmyon's various patents regarding ursolic acid, at its headquarters in Jung-gu, Seoul.

Cardio Diagnostics Holdings, Inc., a pioneering precision cardiovascular medicine company founded by UI faculty Dr. Robert Philibert and UI graduate Dr. Meesha Dogan, today announced the completion of its business combination with Mana Capital Acquisition Corp., a publicly traded special purpose acquisition company.

Eli Lilly has agreed to acquire Akouos for up to $610 million, in a deal intended to expand the buyer’s presence in gene therapy with a focus on treating inner ear disorders. Akouos, which has licensed key technology from the University of Iowa, develops targeted adeno-associated viral (AAV) vector-based gene therapies for conditions that include sensorineural hearing loss, integrating expertise in otology and inner ear drug delivery, as well as gene therapy.

The University of Iowa Research Foundation (UIRF) will host a series of online courses about how to move technology from the university to the marketplace for all University of Iowa faculty, staff, postdocs, and graduate students.

Medical device company Medical 21, founded on technology developed at the UI by Prof. Suresh Raghavan, announced that it has landed a $20 million commitment from an individual investor.